207 related articles for article (PubMed ID: 29388307)
1. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.
Ross DM; Arthur C; Burbury K; Ko BS; Mills AK; Shortt J; Kostner K
Intern Med J; 2018 Feb; 48 Suppl 2():5-13. PubMed ID: 29388307
[TBL] [Abstract][Full Text] [Related]
2. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
4. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Tinsley SM
J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830
[TBL] [Abstract][Full Text] [Related]
5. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
6. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
Perrone S; Massaro F; Alimena G; Breccia M
Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.
Medeiros BC; Possick J; Fradley M
Blood Rev; 2018 Jul; 32(4):289-299. PubMed ID: 29454474
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
9. [Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
Gaál-Weisinger J; Mucsi O; Körösmezey G; Szili B; Eid H; Kiss R; Bödör C; Tárkányi I; Nagy Z; Demeter J
Magy Onkol; 2017 Mar; 61(1):67-74. PubMed ID: 28273190
[TBL] [Abstract][Full Text] [Related]
10. Managing pregnancy in chronic myeloid leukaemia.
Palani R; Milojkovic D; Apperley JF
Ann Hematol; 2015 Apr; 94 Suppl 2():S167-76. PubMed ID: 25814083
[TBL] [Abstract][Full Text] [Related]
11. [Molecular biology and treatment of CML].
Kimura S
Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
Smith CC; Shah NP
Hematology Am Soc Hematol Educ Program; 2011; 2011():121-7. PubMed ID: 22160023
[TBL] [Abstract][Full Text] [Related]
14. Practical management of patients with chronic myeloid leukemia.
Cervantes F; Mauro M
Cancer; 2011 Oct; 117(19):4343-54. PubMed ID: 21413002
[TBL] [Abstract][Full Text] [Related]
15. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
17. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
Matsumura I
Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia: First-line drug of choice.
Jabbour E
Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
